मैट्रिक्स
 
 
अंबाला साराभाई एंटरप्राइजेज > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का अंबाला साराभाई एंटरप्राइजेज - बीएसई: 500009, NSE: AMBASARABH

अंबाला साराभाई एंटरप्राइजेज

बीएसई: 500009  |  NSE: AMBASARABH  |  ISIN: INE432A01017  |  Pharmaceuticals

कंपनी इतिहास - अंबाला साराभाई एंटरप्राइजेज
YEAR                       EVENTS
 1977 - The company was incorporated on 27th June, as a private 
        limited company.  It was converted into a public limited
 company
        on 29th December 1980.  The objects are manufacture of drugs
 and
        pharmaceuticals, industrial chemicals, detergents,
 toiletries,
        electronics, engineering products, paper, glass and plastic
        containers and packaging materials.  The Company also carries
 on
        industrial research and consultancy services.
 
      - The restructuring and reorganisation of various Sarabhai
        Enterprises:
 
      - (a) Elscope Private (Elscope) became the owner of the
 undertaking
        and business of Sarabhai Chemicals, Sarabhai Machinery and
        Bakubhai Ambalal; and
 
      - (b) Ofisade Private Limited (Ofisade) became the owner of 
        undertakings and business of Sarabhai M.Chemicals, Swastik
        Household and Industrial Products, Systronics, Telerad, ORG
        Systems and Operations Research Group, Packart, Cotton &
 Cloth
        and WIPS, Sarabhai Research Centre and Sarabhai Electronics
        Research Centre.
      
      - As a part of the reorganisation, the Company also acquired
 from
        Shahibag Entrepreneurs Pvt. Ltd., the entire share capital of
        Himinonic Detergents Industries Pvt. Ltd. (Himionic) and from
        Kalindi Investments Pvt. Ltd., the entire share capital of 
        Surac Holdings Pvt. Ltd. (Surac).  Thereupon Wadi Holdings
 Pvt.
        Ltd., the respective subsidiaries of Himionic and Surac,
 became
        subsidiaries of the Company.  These in turn hold the shares of
 
        the following joint venture companies.
     
      - A) P.T. Kamaltex, Indonesia: 71,250 No. of equity shares of
 the 
        face value equivalent of U.S. each in P.T. Kamaltex out of
 its
        total paid up share capital equivalent of U.S.$ 37,50,000 
        divided into 3,75,000 equity shares equivalent of U.S. 
 each.
        The International Finance Corporation (U.S.A) and Private 
        Investment Finance Corporation of Asia are major shareholders
 in
        P.T. Kamaltex.
 
      - B) Blue Marlin Ltd., Mauritius: 19,000 No. of equity shares
 of
        the face value of K.Shg. 100 each of Kensara Ltd. out of its
        paidup capital of K.Shg. 20,00,000 divided into 20,000 equity
 
        shares of K.Shg. 100 each.
 
      - The shares in Himionic and Surac were acquired for an
 aggregate
        amount of Rs.473 lakhs.
 
      - The acquisition of the undertakings from Elscope became
 effective
        from 1st July.
 
      - All shares issued to Ofisade Pvt. Ltd.
 
 1978 - The acquisition of the undertakings from Ofisade became
 effective
        from 16th May, but in terms of the sale agreement.
 
      - The Company issued further 11% Non-Convertible bonds of the
 face
        value of Rs.166 lakhs to holding Companies of Sarabhai 
        Enterprises and their subsidiaries to convert demand
 liabilities
        of that amount into deferred credits.
 
 1979 - The Company acquired the entire shareholding of 24,700 No. of
 
        equity shares of Rs.500 each in SG for a total consideration
 of 
        Rs.229.71 lakhs.  While granting permission for this
 acquisition,
        the Reserve Bank of India and the Government of India
 stipulated
        that the undertaking of SG should be taken over by the
 Company.
 
 1981 - The Company proposed to undertake various other schemes of 
        expansion, diversification, modernisation, research and 
        development including those of SG Chemicals &
 Pharmaceuticals,
        Ltd.  All these schemes were to be implemented during the
 period.
 
      - The new plant, machinery and equipment relating to the above
        mentioned schemes were to be installed near the existing
 plant
        where manufacturing and infrastructural facilities were
        available.  In order to meet increase export demand for the
        Company's synthetic detergent `Det' manufacturing facilities
 were
        being set up in the free trade zone at Kandla.
    
      - The Company received industrial licences for the manufacture
 of 
        several drugs and mini-computers/microprocessors-based
 systems
        and computer peripherals. 
 
      - As per the Gujarat High Court Order dated 27th March, SG was
        amalgamated with the Company with effect from 1st April 1979.
 
      - In terms of the Scheme of Amalgamation, the shareholders of
        SG, other than the Company (which held 24,700 No. of equity 
        shares) were allotted 50 fully paid equity shares of Rs.10
 each 
        at par and 27 fully paid 9% non-convertible redeemable bonds
 of
        Rs.100 each and 14 fractions each representing 1/20th of such
 
        bond of Rs.100 each in exchange of 2 shares of SG each of the
        face value of Rs.500.  Thus, the Company issued and allotted a
 
        total of 6,82,500 equity shares of Rs.10 each as fully paid-up
 
        and 3,78,105-9% non-convertible redeemable bonds of the face 
        value of Rs.100 each as fully paid up.
 
      - Standard Pharmaceuticals, Ltd., was amalgamated with the
 Company
        with effect from 1st April.
 
      - In terms of the Scheme of Amalgamation, equity shares of
 Rs.4.61
        lakhs and redeemable bonds of Rs.21.19 lakhs of the Company
 were
        to be issued to the erstwhile shareholders of Standard 
        Pharmaceuticals, Ltd.  Due to this amalgamation, the Company 
        derived the advantage of the industrial licences for the bulk
 
        manufacture of penicillin, Erythomycin, Ampicillin, Vitamin
 C,
        Doxy, doxycycline insulin and other pharmaceutical
 preparations.
        It was also expected to get tax benefit on the loss of
 Standard
        Pharmaceuticals of about Rs.138 lakhs pertaining to the
 previous
        years. 
 
      - The Company issued secured Convertible Debentures of Rs.10
 crores
        on rights basis.  The face value of each debenture was
 Rs.150.
        An amount of Rs.50 each debenture was converted into 5 equity
 
        shares at par on 1st July, 1983.
 
      - Shares sub-divided.  90,000 shares then issued at par:
 4,50,000
        shares to directors/employees of the Company and 1,80,000
 shares
        to business associates of the Company were reserved 83,70,000
        shares offered to the public in February.
 
      - 6,82,500 shares issued to the members of SG Chemicals and 
        Pharmaceuticals Ltd., without payment in cash on its merger.
        31,36,504 bonus shares issued (prop. 1:5).
 
 1982 - The fully automated synthetic detergent plant set up in Kandla
 
        Free Trade Zone was commissioned in the last quarter of the
 year. 
 
      - It was proposed to manufacture sophisticated computer systems
 in
        collaboration with Sperry of U.S.A.  
 
      - It was proposed to amalgamate with the Company Swastik
 Household
        & Industrial Products P. Ltd., Ambernath (Maharashtra) SM
        Chemicals & Electronics P. Ltd. Kandivli, Bombay and Whitco,
 Ltd.
        with effect from 1st July.
 
 1983 - The Scheme of Amalgamation of Swastik Household Industrial 
        Products Pvt. Ltd. (SHIP, Pvt. Ltd) and S.M. Chemicals & 
        Electronics Pvt. Ltd. (SMCEPL) with the Company was sanctioned
 by 
        the Mumbai High Court and approval from the Gujarat High Court
 
        was received on 12th May 1987.
 
      - As per the scheme, the Company issued to the shareholders of
 the
        amalgamating companies, 1,67,500 fully paid equity shares of 
        Rs.10 each and 1,00,050-13% redeemable bonds of the face value
 of 
        Rs.100 each in August 1987.
 
      - 633,33,330 shares allotted in part conversion of debenture
 46,123
        shares allotted without payment in cash to shareholders of
        Standard Pharmaceuticals Ltd., on its merger.
 
 1984 - The Company issued 15% Secured non-convertible debentures for
        Rs.10 crores.  The issue was substantially over-subscribed
 and
        after obtaining consent to retain the excess upto 50% of the
        issue debentures of Rs.15 crores were allotted on 1st
 February
        1985.  Further debentures of Re.1 crore were allotted by
 private
        placement to business associates in June 1985.  The funds
 raised
        through these debentures were utilised for augmenting working
        capital resources.
   
 1985 - In a bid to gain access to the latest innovations in various 
        fields of technological specialisation achieved by World
 leaders
        in the field of bulk drugs and pharmaceuticals, electronics
 and
        synthetic detergents, a Scheme of Reorganisation of Ambalal 
        Sarabhai Enterprises (ASE) Ltd., was evolved.  Under this
 scheme
        it was proposed to divide with effect from 1st July, the
 existing
        operations of ASE between ASE and its two subsidiaries to be 
        named Sarabhai Electronics Ltd., and Sarabhai Surfactants,
 Ltd. 
        and give their shares to the existing shareholders of ASE on
 a
        pro-rata basis without payment as follows: 25 existing shares
 of 
        Rs.10 each of ASE to be automatically exchanged without
 payment
        of 15 shares of Rs.10 each of the restructured ASE, 6 shares
 of
        Rs.10 each of Sarabhai Surfactants Ltd. and 4 shares of Rs.10
 
        each of Sarabhai Electronics Ltd.  Shareholders holding less
 than 
        25 existing shares of ASE or such number of shares as is not
 a
        multiple of 25, will get shares of the same three companies
        approximately in the proportion mentioned above.
 
      - Upon such reorganisation, the Soaps and Detergents division
 of
        ASE along with its related R & D, industrial paper, plastic
        containers and packaging facilities will be transferred as a
        going concern to Sarabhai Surfactants Ltd.  Similarly, the
        Computer division of ASE along with its related R & D will be
        transferred as a going concern to Sarabhai Electronics, Ltd.,
        which will specialise in computers, peripherals and
        instrumentation and represent well known foreign
 manufacturers
        like Sony, Sperry, Packard, Gibson, etc.  Consequently, the
        restructured ASE along with Sarabhai Research Centre will
        specialise mainly in bulk drugs, pharmaceuticals and related
        health care fields.  Negotiations were on for a technical and
        financial collaboration agreement with E.R. Squibb and Sons of
 
        U.S.A.
 
 1986 - The Scheme of Amalgamation for the merger of ASE, of its 
        subsidiaries Himionic holdings Ltd., Wadi Holdings, Ltd., 
        Surac Holdings, Ltd., Perion Holdings, Ltd., Wadi Financiers
 and
        Investments, Ltd., and Shahibag Investments Ltd. with effect
 from
        1st July was sanctioned by the High Courts of Gujarat and
 Mumbai.
        
 1987 - The Gujarat High Court gave its sanction for the Scheme of 
        Amalgamation on 24th December.
 
      - SG Chemicals & Pharmaceuticals, Ltd. (SG), formerly known as 
        Suhrid Geigy, Ltd., was a Company in which Ciba-Geigy Ltd.,
        Basle, Switzerland and its associates held 47 1/2% of the
 paid
        up capital.  Ciba-Geigy discotinued its technical
 collaboration
        with SG with effect from 1st Junuary, 1976.
 
      - As per the scheme of arrangement Sarabhai Electronics Ltd.
 (SEL)
        in which the Electronics division of ASE had been vested,
 issued
        35,82,536 of its equity shares to the shareholders of the
 Company
        
      - 1,67,400 No. of Equity shares allotted without payment in cash
 to 
        members of SHIP Pvt. Ltd., and SMCPL on their merger.
 
 1988 - The Company suffered a severe setback due to non-availability
 of
        working funds resulting in underutilisation of capacity.
 
      - The Company entered into an understanding with Bristol-Myers 
        Squibb Corporation, U.S.A for technical know-how in the 
        manufacture of pharmaceuticals and penicillin.  This was done
 
        with a view to takeover as a going concern the existing 
        undertaking of Synbiotics Ltd. for the manufacture of bulk
 drugs.
 
      - An agreement was concluded on 2nd August for the sale of 
        9,38,850 No. of equity shares of Rs.10 each held by the
 Company
        in Swastik Surfactants Ltd. (SSL) for a consideration of Re.1
        crore and for discharge of SSL of its liability of ASE and 
        Associates including Rs.11.66 crores in terms of the scheme
 of
        arrangement.  This sale was completed by delivery of shares
 on
        3rd November.
 
      - The Company disinvested in entire shareholding of 500 No. of
        equity shares of Rs.1000 each of its wholly owned subsidiary
 SG
        Chemicals and Dyes Trading Ltd., for a consideration of Rs.200
 
        lakhs.
 
      - 35,82,536 shares cancelled consequent upon the transfer of
 assets 
        to Sarabhai Electronics Ltd.
 
 1989 - Government granted the industrial licence for the project.
        Government approval was also received for M/s. Bristol -
 Myers
        Squibb (USA) to participate to the extent of 8,00,000 shares
 in
        the equity capital of the Company.
 
      - The Company proposed to issue fresh equity of Rs.1870 lakhs
 to
        shareholders/public for the project.
 
      - The Company entered into technical collabortion agreements
 with
        Avesta (Sweden) and Pannevis (Netherlands) for the
 manufacture
        of special process equipments and screen making equipment.
 
 1990 - 171,29,622 shares allotted as fully paid-up to bondholders of
        series `A' and `B' on redemption of the said bonds.
 
 1991 - The Company had received necessary permission under the FERA,
 
        1973 for acquiring 6,000 equity shares of Rs.1000 each of the
        subsidiary Company, Synbiotics Ltd., which were being held by
        E.R. Squibb & Sons Inc.  Necessary approvals from other 
        authorities were awaited.
 
      - The Company revalued most of its assets excluding those of 
        Standard Pharmaceuticals, Calcutta, as on 31st March.  The 
        surplus of Rs.1605.75 lakhs representing the increase in the 
        value of land was credited to capital reserve No.1 and the 
        surplus of Rs.5032.45 lakhs representing increase in the
 value
        of other major assets was credited to capital reserve No.2.
 
      - The objects of the public issue of equity capital were (i) to
        strengthen the financial resources of the Company to maintain
 the
        tempo of its rapid growth and (ii) to make its shareholding
 more
        broadbased.
 
 1993 - 2,70,39,214 shares allotted on conversion of 15%
 non-convertible
        debentures and 13.5% convertible debentures in terms of a
 special
        resolution passed in EGM.
 
 1994 - The Company introduced highly purified insulin injections 
        manufactured under technical collaboration with Biobras of
 Brazil
        which received enthusiastic response from the medical
 profession.
 
 1995 - The full range of highly purified procine insulin launched
 and
        manufacturing started for human insulin products.  An oral
        formulation `Contramal' manufactured in collaboration with
        Grunenthal of Germany was launched.
 
      - The Electronics division introduced an
 auto-scanning/computing
        Densitometer.
 
      - 19,66,538 shares issued at an issue price of Rs.22.25 per
 share 
        to Sarabhai Group Investments Companies, towards settlement
 of
        their loans and interest due thereon.
 
 1996 - The Company introduced new `Cardiovascular' anti-inflammatory
 and
        antiheptic ulcer drugs in addition to extension of the
 existing
        products.
 
      - The Company obtained industrial licences for the manufacture
 of
        (i) fatty acids from minor edible oils, (ii) Sorbitol and 
        (iii) increcal (cycocel technical) an agrochemical.  Letters
 of
        intent were in hand for the manufacture of (i) Chlorine and
 its
        salts and (ii) screen making equipment.  Industrial licence
 for
        the manufacture of (i) electronic measuring and testing 
        instrument, (ii) closed cirucuit television systems and (iii)
        Special process equipment including vacuum dryers,
 sterilisers,
        evaporators, crystallisers, heat exchangers etc. were in the
        process of being endorsed in the name of the Company.  The
        Company's application for the manufacture of computer
 peripherals
        and micro-processors was pending with Government.
 
 2000
 
 -The Ahmedabad-based Cadila Healthcare of the Zydus group and the
 Baroda-based Ambalal Sarabhai Enterprises (ASE) have joined hands to
 form a veterinary products joint venture.
 
 2007
 
 -Ambalal Sarabhai Enterprises Ltd has appointed Mr. B S Bohra as
 Additional Director of the Company.
 
 2008
 
 -The Company has acquired 100% paid up share capital of Suvik Hi-tek
 Pvt. Ltd., (SHPL), a small scale industry, based at Gandhinagar, who
 is engaged in the business of manufacture and marketing of
 Pharmaceuticals - Formulations and thereby SHPL is now became a
 wholly owned subsidiary of the Company.
 
 2012
 -Ms. Chaula Shastri has joined the Board of Directors as a Whole-Time
 Director of the Company.
 
 2016
 -Address of the Company's registered office has been changed from
 Sarabhai Campus Gorwa Road,Vadodara -390023 To Shanti sadan Mirzapur
 Road Ahmedabad - 380001.
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `750 Cr की खरीदारी की
  • MARKET CUES : DIIs ने कैश में `703 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `725 Cr की बिकवाली की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `661 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स ऑप्शंस में `861 Cr की बिकवाली की
  • MARKET CUES : स्टॉक फ्यूचर्स में `681 Cr की बिकवाली की
  • CS ON INFOSYS : Underperform रेटिंग, लक्ष्य बढ़ाकर `720/Sh
  • JEFFERIES ON INFOSYS : BUY रेटिंग, लक्ष्य घटाकर `915/Sh
  • CITI ON INFOSYS : BUY रेटिंग, लक्ष्य `900/Sh
  • UBS ON INFOSYS : Neutral रेटिंग, लक्ष्य `900/Sh

अभी देखें

ट्रेडर्स हॉटलाइन

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.